IUPAC/Chemical Name
L-alanine compound with L-glutamic acid and glycine (1:1:1)
InChi Key
RBPVKPJDVPPRMI-AVXONLMPSA-N
InChi Code
InChI=1S/C5H9NO4.C3H7NO2.C2H5NO2/c6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;3-1-2(4)5/h3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1,3H2,(H,4,5)/t3-;2-;/m00./s1
SMILES Code
N[C@@H](CCC(O)=O)C(O)=O.N[C@@H](C)C(O)=O.NCC(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
311.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G. WITHDRAWN: Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2011 May 11;(5):CD001042. doi: 10.1002/14651858.CD001042.pub2. Review. PubMed PMID: 21563128.
2: Okada H. [BPH pharmacotherapy (miscellaneous)]. Nihon Rinsho. 2002 Dec;60 Suppl 11:367-72. Review. Japanese. PubMed PMID: 12599602.
3: Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001042. Review. Update in: Cochrane Database Syst Rev. 2011;(5):CD001042. PubMed PMID: 10796739.
4: MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000 May;85(7):836-41. Review. PubMed PMID: 10792162.
5: Mahoney JE. Plant extracts in the medical management of benign prostatic hyperplasia: fact or fiction? Can J Urol. 1995 May;2(2):125-9. PubMed PMID: 12803719.
6: Kumamoto Y, Tsukamoto T, Yachiku S, Kaneko S, Koyanagi T, Togashi M, Maru A, Tsuchida S, Nishizawa O, Orikasa S, et al. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy]. Hinyokika Kiyo. 1990 Oct;36(10):1213-32. Japanese. PubMed PMID: 1702262.
7: Maekawa M, Kishimoto T, Yasumoto R, Wada S, Harada T, Ohara T, Okajima E, Hirao Y, Ohzono S, Shimada K, et al. [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost]. Hinyokika Kiyo. 1990 Apr;36(4):495-516. Japanese. PubMed PMID: 1696065.
8: Yamaguchi O, Shiraiwa Y, Kobayashi M, Yokota T, Ohinata M, Aoki H, Tsuzuki T, Ohori M. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. Urol Int. 1990;45 Suppl 1:40-6. PubMed PMID: 1690481.
9: Aito K, Watsubo E. [The conservative treatment of prostatic hypertrophy with Paraprost]. Hinyokika Kiyo. 1972 Jan;18(1):41-4. Japanese. PubMed PMID: 4112552.
